Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs
A cost-effectiveness model was designed to explore the effect of adding a new angiotensin-II inhibitor, telmisartan, to the therapeutic options for treating mild-to-moderate uncomplicated hypertension. Incorporating the cost of drugs, physician visits, and adverse-event treatments, the model concluded that availability of telmisartan on formulary may shorten the mean time and costs to control. The stability of the initial findings over a range of sensitivity analyses lends credence to the model conclusions that availability of telmisartan on formulary improves the therapeutic options of care for hypertension
Richter, A., Gondek, K., Ostrowski, C., Dombeck, M., & Lamb, S. (2001). Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs. Managed Care Interface, 14(7), 61-69.